Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma

Journal of Clinical Oncology

Volumn 30, Issue 16, 2012, Pages 1960-1965

  Jakubowiak, Andrzej J ^a,b   Benson, Don M ^b,c   Bensinger, William ^d   Siegel, David S D ^e   Zimmerman, Todd M ^f   Mohrbacher, Ann ^g   Richardson, Paul G ^b,i   Afar, Daniel E H ^h   Singhal, Anil K ^h   Anderson, Kenneth C ^b,i  

^a UNIVERSITY OF MICHIGAN   (United States)

^b Multiple Myeloma Research Consortium   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

^e HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^h Abbott Biotherapeutics   (United States)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; ELOTUZUMAB;

ACUTE HEART INFARCTION; ADULT; AGED; AGITATION; ANEMIA; ARTICLE; BILIRUBIN BLOOD LEVEL; BONE PAIN; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RELAPSE; CHILL; CLINICAL ARTICLE; CONSTIPATION; COUGHING; CREATININE BLOOD LEVEL; DIARRHEA; DIZZINESS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FEVER; GASTROENTERITIS; HEADACHE; HUMAN; HYPERCALCEMIA; HYPERGLYCEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; INSOMNIA; LEUKOPENIA; LIMB PAIN; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MALE; MAXIMUM TOLERATED DOSE; METABOLIC ENCEPHALOPATHY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NEURALGIA; NEUTROPENIA; NONCARDIAC CHEST PAIN; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RASH; SENSORY NEUROPATHY; SEPSIS; SIDE EFFECT; SUICIDAL IDEATION; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MULTIPLE MYELOMA; PYRAZINES; RECURRENCE;

EID: 84862672400     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.37.7069     Document Type: Article

References (16)

1. Kyle RA, Rajkumar SV: Multiple myeloma. N Engl J Med 351:1860-1873, 2004
2. Kumar SK, Rajkumar SV, Dispenzieri A, et al: Improved survival in multiple myeloma and the impact of novel therapies. Blood 111:2516-2520, 2008
3. Jemal A, Siegel R, Xu J, et al: Cancer statistics, 2010. CA Cancer J Clin 60:277-300, 2010
4. Imrie K, Esmail R, Meyer RM: The role of high-dose chemotherapy and stem-cell transplantation in patients with multiple myeloma: A practice guideline of the Cancer Care Ontario Practice Guidelines Initiative. Ann Intern Med 136:619-629, 2002 (Pubitemid 34407047)
5. Mark T, Niesvizky R, Coleman M: Novel agents in myeloma: An exciting saga. Cancer 115:236-242, 2009
6. Biogen Idec and Genentech: Rituxan (rituximab): Full prescribing information. South San Francisco, CA, Biogen Idec and Genentech, 2010
7. Tai YT, Dillon M, Song W, et al: Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood 112:1329-1337, 2008
8. Hsi ED, Steinle R, Balasa B, et al: CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res 14:2775-2784, 2008
9. Zonder J, Singhal A, Bensinger W, et al: Dose escalation study of elotuzumab (HuLuc63) in patients with relapsed/refractory multiple myeloma: Interim results. Presented at the Annual Meeting of the American Society of Hematology, Orlando, FL, December 6-9, 2008
10. Lonial S, Vij R, Harousseau J-L, et al: Elotuzumab in combination with lenalidomide and lowdose dexamethasone in patients with relapsed/refractory multiple myeloma: Interim results of a phase 1 study. Presented at the Annual Meeting of the American Society of Hematology, Orlando, FL, December 3-7, 2010
11. Richardson PG, Moreau P, Jakubowiak AJ, et al: Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: Interim results of a phase 2 study. Presented at the Annual Meeting of the American Society of Hematology, Orlando, FL, December 3-7, 2010
12. van Rhee F, Szmania SM, Dillon M, et al: Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Mol Cancer Ther 8:2616-2624, 2009
13. Bladé J, Samson D, Reece D, et al: Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation: Myeloma Subcommittee of the EBMT - European Group for Blood and Marrow Transplant. Br J Haematol 102:1115-1123, 1998 (Pubitemid 28435189)
14. Richardson PG, Barlogie B, Berenson J, et al: A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609-2617, 2003 (Pubitemid 36741588)
15. Richardson PG, Sonneveld P, Schuster MW, et al: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487-2498, 2005 (Pubitemid 41007864)
16. Orlowski RZ, Nagler A, Sonneveld P, et al: Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: Combination therapy improves time to progression. J Clin Oncol 25:3892-3901, 2007 (Pubitemid 47477266)